Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry
Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry
复制标题
DOI：
10.1016/j.aca.2011.02.038
复制
发表时间：
2011-04-08
影响因子：
6.2
通讯作者：
Li, Lanjuan
中科院分区：
文献类型：
--
作者：
Cao, Hongcui;Huang, Haijun;Li, Lanjuan
采用超高效液相色谱四极杆飞行时间质谱仪(UPLC/Q-TOF MS)研究了健康人、肝硬变和肝细胞癌患者的粪便代谢组。然后使用偏最小二乘潜在结构判别分析(PLS-DA)模型对该方法检测到的代谢特征进行统计处理，以区分健康和疾病状态。FL-DA还被用来区分肝硬变和肝细胞癌应激的粪便代谢物，并识别在粪便代谢物中表达显著不同的肝硬变和肝细胞癌的潜在生物标志物。模式识别分析的记分图将肝硬变和肝细胞癌患者与健康人区分开来。根据VIP值的重要性变量和S曲线，6种代谢产物被认为是潜在的生物标志物，与健康人相比，肝硬变和肝癌患者的溶血磷脂酰胆碱显著增加，胆汁酸和胆汁色素显著减少。结果表明，UPLC-MS是一种有效、简便的方法，可用于粪便标本的筛选，并有助于早期诊断肝硬化和肝细胞癌。(C)2011爱思唯尔B.V.保留所有权利。
Fecal metabolome of healthy humans and patients suffering from liver cirrhosis and hepatocellular carcinoma (HCC) were studied using ultra performance liquid chromatography coupled to quadrupole-time-of-flight mass spectrometry (UPLC/Q-TOF MS). Metabolic features detected by the method were then statistically treated using partial least squares to latent structure-discriminant analysis (PLS-DA) models to discriminate between healthy and diseased states. PLS-DA was also used to discriminate between cirrhosis and HCC stressed fecal metabolomes and to identify potential biomarkers for cirrhosis and HCC that are expressed at significantly different amounts in fecal metabolomes. Score plots of pattern recognition analysis distinguished liver cirrhosis and HCC patients from healthy humans. Based on the variable of importance in the project (VIP) values and S-plots, six metabolites were considered as potential biomarkers with a strong increase in lysophosphatidylcholines and a dramatic decrease in bile acids and bile pigments in patients with liver cirrhosis and HCC in comparison with healthy humans. Results demonstrate the potential of UPLC-MS as an efficient and convenient method that can be applied to screen fecal samples and aid in the early diagnosis of cirrhosis and hepatocellular carcinoma. (C) 2011 Elsevier B.V. All rights reserved.